Skip to main content
Erschienen in: International Journal of Diabetes in Developing Countries 2/2019

15.02.2019 | Original Article

Clinical and biochemical characteristics and the association of angiotensin type 1 receptor with normoalbuminuric chronic kidney disease among South Indian type 2 diabetes population

verfasst von: Vijay Viswanathan, Ezhilarasi Krishnamoorthy, Satyavani Kumpatla, Bliss Lunghar, Anju Soni, Anitha Rani

Erschienen in: International Journal of Diabetes in Developing Countries | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study was to determine the clinical and biochemical characteristics especially cystatin C and the association of angiotensin type I receptor (AT1R) gene polymorphism with normoalbuminuric chronic kidney disease (NACKD) among South Indian type 2 diabetes (T2DM) population.

Material and methods

The study comprised of 308 (M:F 190:118) subjects with T2DM categorized into three groups. Group I: T2DM patients without albuminuria (NA) and estimated glomerular filtration rate (eGFR) > 90 ml/min/1.73m2 (n = 110); group II: T2DM patients with albuminuric chronic kidney disease (CKD) with eGFR < 60 ml/min/1.73m2 (n = 98); and group III: T2DM patients with normoalbuminuric CKD (NACKD) and eGFR < 60 ml/min/1.73m2 (n = 100). The eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) formula. Cystatin C was measured by particle-enhanced immunoturbidimetric assay. AT1R gene polymorphism was analyzed using the PCR-RFLP method.

Results

The biochemical parameters urea, creatinine, post prandial glucose, HbA1c, triglycerides, cystatin C levels, erythrocyte sedimentation rate (ESR), and diastolic blood pressure were lower and the levels of calcium were higher in normoalbuminuric CKD subjects as compared to albuminuric CKD subjects. The AT1R genotypic distribution of AA, AC, and CC was 80.2%, 19.8%, and 0% in NACKD, and 95.1%, 4.9%, and 0% in CKD subjects. The distribution of allelic frequencies of A and C allele in NACKD was 90.1% and 9.9%, and in CKD, it was 97.6% and 2.4% respectively. The relative risk of AC (p = 0.08) genotype and C (p = 0.01) allele in NACKD was 4 times higher as compared to CKD.

Conclusion

The present study highlighted that the clinical and biochemical parameters showed significant differences especially cystatin C whose levels increased in normoalbuminuric CKD subjects as compared to normoalbuminuric subjects. Significant association of AGTR1 A1166C polymorphism was observed in normoalbuminuric CKD subjects as compared to CKD subjects with T2DM.
Literatur
1.
Zurück zum Zitat Afghahi H, Cederholm J, Eliasson B, Zethelius B, Gudbjornsdottir S, Hadimeri H, et al. Risk factors for the development of albuminuria and renal impairment in type 2 diabetes—the Swedish National Diabetes Register (NDR). Nephrol Dial Transplant. 2011;26:1236–43.CrossRefPubMed Afghahi H, Cederholm J, Eliasson B, Zethelius B, Gudbjornsdottir S, Hadimeri H, et al. Risk factors for the development of albuminuria and renal impairment in type 2 diabetes—the Swedish National Diabetes Register (NDR). Nephrol Dial Transplant. 2011;26:1236–43.CrossRefPubMed
2.
Zurück zum Zitat Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Bhansali A, Sud K, et al. ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy. DNA Cell Biol. 2009;28:141–50.CrossRefPubMed Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Bhansali A, Sud K, et al. ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy. DNA Cell Biol. 2009;28:141–50.CrossRefPubMed
3.
Zurück zum Zitat Boronat M, Garcia-Canton C, Quevedo V, Lorenzo DL, Lopez-Rios L, Batista F, et al. Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitus. Ren Fail. 2014;36(2):166–70.CrossRefPubMed Boronat M, Garcia-Canton C, Quevedo V, Lorenzo DL, Lopez-Rios L, Batista F, et al. Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitus. Ren Fail. 2014;36(2):166–70.CrossRefPubMed
4.
Zurück zum Zitat Bostom AG, Dworkin LD. Cystatin C measurement: improved detection of mild decrements in glomerular filtration rate verses creatinine-based estimates? Am J Kidney Dis. 2000;36(1):205–7.CrossRefPubMed Bostom AG, Dworkin LD. Cystatin C measurement: improved detection of mild decrements in glomerular filtration rate verses creatinine-based estimates? Am J Kidney Dis. 2000;36(1):205–7.CrossRefPubMed
5.
Zurück zum Zitat Buraczynska M, Ksiazek P, Drop A, Zaluska W, Spasiewicz D, Ksiazek A. Genetic polymorphisms of the renin–angiotensin system in end-stage renal disease. Nephrol Dial Transplant. 2006;21:979–83.CrossRefPubMed Buraczynska M, Ksiazek P, Drop A, Zaluska W, Spasiewicz D, Ksiazek A. Genetic polymorphisms of the renin–angiotensin system in end-stage renal disease. Nephrol Dial Transplant. 2006;21:979–83.CrossRefPubMed
6.
Zurück zum Zitat Chang HR, Cheng CH, Shu KH, Chen CH, Lian JD, Wu MY. Study of the polymorphism of angiotensinogen, angiotensin-converting enzyme and angiotensin receptor in type II diabetes with end-stage renal disease in Taiwan. J Chin Med Assoc. 2003;66(1):51–6.PubMed Chang HR, Cheng CH, Shu KH, Chen CH, Lian JD, Wu MY. Study of the polymorphism of angiotensinogen, angiotensin-converting enzyme and angiotensin receptor in type II diabetes with end-stage renal disease in Taiwan. J Chin Med Assoc. 2003;66(1):51–6.PubMed
7.
Zurück zum Zitat Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368:581–8.CrossRefPubMed Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368:581–8.CrossRefPubMed
8.
Zurück zum Zitat Dayanidhi S, Ramadevi K, Periyandavar I. Serum cystatin C and microalbumin in the detection of early nephropathy in type 2 diabetic patients. Int J Pharm Bio Sci. 2015;6:1208–14. Dayanidhi S, Ramadevi K, Periyandavar I. Serum cystatin C and microalbumin in the detection of early nephropathy in type 2 diabetic patients. Int J Pharm Bio Sci. 2015;6:1208–14.
9.
Zurück zum Zitat Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–6.CrossRefPubMed Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–6.CrossRefPubMed
10.
Zurück zum Zitat Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia. 1996;39:1569–76.CrossRefPubMed Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia. 1996;39:1569–76.CrossRefPubMed
11.
Zurück zum Zitat Fradin S, Goulet-Salmon B, Chantepie M, Grandhomme F, Morello R, et al. Relationship between polymorphisms in the renin–angiotensin system and nephropathy in type 2 diabetic patients. Diabetes Metab. 2002;28(1):27–32.PubMed Fradin S, Goulet-Salmon B, Chantepie M, Grandhomme F, Morello R, et al. Relationship between polymorphisms in the renin–angiotensin system and nephropathy in type 2 diabetic patients. Diabetes Metab. 2002;28(1):27–32.PubMed
12.
Zurück zum Zitat Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61:2165–75.CrossRefPubMed Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61:2165–75.CrossRefPubMed
13.
Zurück zum Zitat Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving HH. Genetic variation in the renin– angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol. 2003;14:2843–50.CrossRefPubMed Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving HH. Genetic variation in the renin– angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol. 2003;14:2843–50.CrossRefPubMed
14.
Zurück zum Zitat JAMA Article : Early Release Article, posted May 14, 2003: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA Article : Early Release Article, posted May 14, 2003: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
15.
Zurück zum Zitat Jeon YK, Kim MR, Huh JE, Mok JY, Song SH, Kim SS, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci. 2011;26:258–63.CrossRefPubMedPubMedCentral Jeon YK, Kim MR, Huh JE, Mok JY, Song SH, Kim SS, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci. 2011;26:258–63.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.CrossRefPubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.CrossRefPubMed
18.
Zurück zum Zitat Lim LM, Kuo HT, Kuo MC, Chiu YW, Lee JJ, Hwang SJ, et al. Low serum calcium is associated with poor renal outcomes in chronic kidney disease stages 3-4 patients. BMC Nephrol. 2014;15:183.CrossRefPubMedPubMedCentral Lim LM, Kuo HT, Kuo MC, Chiu YW, Lee JJ, Hwang SJ, et al. Low serum calcium is associated with poor renal outcomes in chronic kidney disease stages 3-4 patients. BMC Nephrol. 2014;15:183.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Maniatis T, Fritsch EF, Sambrook J, et al. Molecular cloning: a laboratory manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory; 1982. p. 149–51. Maniatis T, Fritsch EF, Sambrook J, et al. Molecular cloning: a laboratory manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory; 1982. p. 149–51.
20.
Zurück zum Zitat Mauro B, Cesar G, Virginia Q, Lorenzo DL, Laura L, Fatima B, et al. Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitus. Ren Fail. 2013:1525–6049. Mauro B, Cesar G, Virginia Q, Lorenzo DL, Laura L, Fatima B, et al. Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitus. Ren Fail. 2013:1525–6049.
21.
Zurück zum Zitat Modi KS, Rao VK. Atheroembolic renal disease. J Am Soc Nephrol. 2001;12(8):1781–7.PubMed Modi KS, Rao VK. Atheroembolic renal disease. J Am Soc Nephrol. 2001;12(8):1781–7.PubMed
22.
Zurück zum Zitat Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002;61:1453–61.CrossRefPubMed Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002;61:1453–61.CrossRefPubMed
23.
Zurück zum Zitat Osawa N, Koya D, Araki S, Uzu T, Tsunoda T, Kashiwagi A, et al. Combinational effect of genes for the renin–angiotensin system in conferring susceptibility to diabetic nephropathy. J Hum Genet. 2007;52:143–51.CrossRefPubMed Osawa N, Koya D, Araki S, Uzu T, Tsunoda T, Kashiwagi A, et al. Combinational effect of genes for the renin–angiotensin system in conferring susceptibility to diabetic nephropathy. J Hum Genet. 2007;52:143–51.CrossRefPubMed
24.
Zurück zum Zitat Parving H-H, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, editor. Brenner and Rector’s the kidney. 7th ed. Philadelphia: WB Saunders; 2004. p. 1777–818. Parving H-H, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, editor. Brenner and Rector’s the kidney. 7th ed. Philadelphia: WB Saunders; 2004. p. 1777–818.
25.
Zurück zum Zitat Prasad P, Tiwari AK, Prasanna KM, Ammini AC, Gupta A. Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. BMC Med Genet. 2006;7:1–9.CrossRef Prasad P, Tiwari AK, Prasanna KM, Ammini AC, Gupta A. Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. BMC Med Genet. 2006;7:1–9.CrossRef
26.
Zurück zum Zitat Price CP, Finney H. Developments in the assessment of glomerular filtration rate. Clin Chem Acta. 2000;297(1–2):55–66.CrossRef Price CP, Finney H. Developments in the assessment of glomerular filtration rate. Clin Chem Acta. 2000;297(1–2):55–66.CrossRef
27.
Zurück zum Zitat Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007;53:480–8.CrossRefPubMed Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007;53:480–8.CrossRefPubMed
28.
Zurück zum Zitat Remuzzi G, Ruggenenti P. Overview of randomised trials of ACE inhibitors. Lancet. 2006;368:555–6.CrossRefPubMed Remuzzi G, Ruggenenti P. Overview of randomised trials of ACE inhibitors. Lancet. 2006;368:555–6.CrossRefPubMed
29.
Zurück zum Zitat Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, for the UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes. U.K. Prospective Diabetes Study 74. Diabetes. 2006;55:1832–9.CrossRefPubMed Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, for the UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes. U.K. Prospective Diabetes Study 74. Diabetes. 2006;55:1832–9.CrossRefPubMed
30.
Zurück zum Zitat Rigalleau V, Beauvieux MC, Le Moigne F, Lasseur C, Chauveau P, Raffaitin C, et al. Cystatin C improves the diagnosis and stratification of chronic kidney disease, and the estimation of glomerular filtration rate in diabetes. Diabetes Metab. 2008;34:482–9.CrossRefPubMed Rigalleau V, Beauvieux MC, Le Moigne F, Lasseur C, Chauveau P, Raffaitin C, et al. Cystatin C improves the diagnosis and stratification of chronic kidney disease, and the estimation of glomerular filtration rate in diabetes. Diabetes Metab. 2008;34:482–9.CrossRefPubMed
31.
Zurück zum Zitat Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H. Predictors of mortality in insulin dependent diabetes: 10 year follow up study. BMJ. 1996;313:779–84.CrossRefPubMedPubMedCentral Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H. Predictors of mortality in insulin dependent diabetes: 10 year follow up study. BMJ. 1996;313:779–84.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G. Angiotensin converting enzyme insertion deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol. 2008;3(5):511–25.CrossRef Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G. Angiotensin converting enzyme insertion deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol. 2008;3(5):511–25.CrossRef
33.
Zurück zum Zitat Satyavani K, Hemalatha K, Shabana T, Viswanathan V. The costs of treating long term diabetic complications in a developing country: a study from India. J Assoc Physicians India. 2013;61:102–9. Satyavani K, Hemalatha K, Shabana T, Viswanathan V. The costs of treating long term diabetic complications in a developing country: a study from India. J Assoc Physicians India. 2013;61:102–9.
34.
Zurück zum Zitat Smith HW. The kidney: structure and function in health and disease. New York: Oxford University Press; 1951. p. 63–6. Smith HW. The kidney: structure and function in health and disease. New York: Oxford University Press; 1951. p. 63–6.
35.
Zurück zum Zitat Tomino Y, Makita Y, Shike T, Gohda T, Haneda M, Kikkawa R. Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients. Nephron. 1999;82:139–44.CrossRefPubMed Tomino Y, Makita Y, Shike T, Gohda T, Haneda M, Kikkawa R. Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients. Nephron. 1999;82:139–44.CrossRefPubMed
36.
Zurück zum Zitat Rinnno H, Iijima T, Takeda Y, Shimizu A, Kobata M, et al. Serum cystatin c levels in hypertensive type 2 diabetic nephropathy patients after treatment with angiotensin converting enzyme (ACE) inhibitor temocapril. Acta Nephrol. 2002;16:62–5. Rinnno H, Iijima T, Takeda Y, Shimizu A, Kobata M, et al. Serum cystatin c levels in hypertensive type 2 diabetic nephropathy patients after treatment with angiotensin converting enzyme (ACE) inhibitor temocapril. Acta Nephrol. 2002;16:62–5.
37.
Zurück zum Zitat Young RP, Chan JC, Critchley JA, Poon E, et al. Angiotensinogen T235 and ACE insertion/deletion polymorphisms associated with albuminuria in Chinese type 2 diabetic patients. Diabetes Care. 1998;21:431–437 Young RP, Chan JC, Critchley JA, Poon E, et al. Angiotensinogen T235 and ACE insertion/deletion polymorphisms associated with albuminuria in Chinese type 2 diabetic patients. Diabetes Care. 1998;21:431–437
Metadaten
Titel
Clinical and biochemical characteristics and the association of angiotensin type 1 receptor with normoalbuminuric chronic kidney disease among South Indian type 2 diabetes population
verfasst von
Vijay Viswanathan
Ezhilarasi Krishnamoorthy
Satyavani Kumpatla
Bliss Lunghar
Anju Soni
Anitha Rani
Publikationsdatum
15.02.2019
Verlag
Springer India
Erschienen in
International Journal of Diabetes in Developing Countries / Ausgabe 2/2019
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-019-00719-0

Weitere Artikel der Ausgabe 2/2019

International Journal of Diabetes in Developing Countries 2/2019 Zur Ausgabe